Wound News and Research

RSS

World's first gene therapy trial aimed at preventing cancer

The concept seems straightforward. If, at its heart, cancer is a disease of genes, then giving patients new genes should disarm cancer. Such treatment would replace missing or faulty genes that keep cell growth in check, or would flush the body with "super genes" that could attack and destroy cancer.

5 May 2004

$FDA approves INFUSE® bone graft which improves fracture healing$

FDA approves INFUSE® bone graft which improves fracture healing

Medtronic, Inc. has announced that the U.S. Food and Drug Administration (FDA) approved the use of INFUSE® Bone Graft in the treatment of acute, open fractures of the tibial shaft, a long bone in the lower leg. The approval broadens the indications for INFUSE Bone Graft, a product that has been used since 2002 in spinal surgery with metallic cages to treat tens of thousands of patients.

4 May 2004

Wyeth gets FDA approval for a novel protein device that enhances bone healing

Wyeth have announced that the FDA has approved rhBMP-2/ACS (recombinant human Bone Morphogenetic Protein-2/Absorbable Collagen Sponge), a novel protein device that enhances bone healing, for use in the treatment of acute, open tibia shaft fractures in adults.

3 May 2004

Hand surgeons warn of gardening dangers

The American Society for Surgery of the Hand (ASSH) recommends gardeners take the proper precautions to prevent hand-related injuries before digging or planting in the garden this spring. According to the Consumer Product Safety Commission (CPSC), emergency rooms treat more than 400,000 outdoor garden-tool-related accidents each year.

27 Apr 2004

Biological bandages are being successfully used to treat patients with severe burns

Doctors have been impressed with the rapid recovery rates instigated by the ‘tailor-made ’ discs, which have been devised by a research team at the Sheffield company, CellTran, with financial support from the Wellcome Trust biomedical research charity and the White Rose Technology Seedcorn Fund. They will be officially launched at the British Burn Association’s annual meeting in Manchester tomorrow (28th).

27 Apr 2004

Third Melbourne hospital infected by Serratia bacteria

A spokeswoman for The Royal Women's Hospital says three babies so far have been isolated after they were found to be carrying the serratia bacteria.

22 Apr 2004

Second-hand smoke scars and affects healing

Researchers at the University of California, Riverside have found that breathing “second-hand” smoke reduces the speed at which wounds heal, leading to greater levels of scarring.

17 Apr 2004

Growth hormones combat Crohn’s disease, cardiac disorders and improve fertility in invitro fertilisation

New treatments for breast cancer, skin and wound healing and obesity will be revealed at an international conference in Cairns, Australia next week.

13 Apr 2004

Antimicrobial alginate dressing protects the wound with silver

Johnson & Johnson Wound Management today announced the introduction of SILVERCEL™ antimicrobial alginate dressing, providing the protection of silver and the absorption of alginate.

13 Apr 2004

Leeches back to relieve pain

The leech was indispensable in 19th Century medicine for bloodletting, a practice believed to be a cure for anything from headaches to gout. Leeching was largely abandoned as medical science advanced, only occasionally being called upon to treat bruising and black eyes.

13 Apr 2004

Coronary stent drives Johnson & Johnson to record profits

Johnson & Johnson today announced sales for the first quarter of $11.6 billion, an increase of 17.7% over the prior year. The increase represented operational growth of 12.3% and a currency impact of 5.4%. Domestic sales were up 15.1%, while international sales increased 21.8%, including operational growth of 7.8% and a positive currency impact of 14.0%.

13 Apr 2004

Continuous insulin monitoring does not raise hospital costs

Patients with diabetes whose glucose is continually monitored after coronary bypass artery graft surgery do not incur higher medical costs despite the additional testing, Penn State Diabetes Center researchers report.

12 Apr 2004

How rat's genetic blueprint stacks up against those of mice and humans

An international research team, supported by the National Institutes of Health (NIH), today announced it has completed a high-quality, draft sequence of the genome of the laboratory rat, and has used that data to explore how the rat's genetic blueprint stacks up against those of mice and humans.

31 Mar 2004

Novel uses for bacterial cellulose, artificial blood vessels, bioengineered wound dressing

New and unique products created from bacterial cellulose — from electronic paper to treatment for wounds — will highlight a one-day symposium at the 227th national meeting of the American Chemical Society, the world's largest scientific society.

30 Mar 2004

Emerging technologies in tissue engineering and regenerative medicine analysis

Pathbreaking developments in tissue engineering and regenerative therapies are facilitating the design and growth of new organs in labs using biopolymer scaffolds and matrices. Analysis of potential markets for tissue engineering reveals that basic problems such as vascularity must be solved before such implants can gain acceptance as standard treatment methods.

30 Mar 2004

Snake venom launders out all stains

Purveyors of snake oil and its mythical powers may not have had it all wrong, if preliminary findings with the Florida cottonmouth, bloodstains and a washing machine stay on target. An enzyme extracted from the viper's venom appears to help launder out notoriously stubborn blood spots on clothing.

29 Mar 2004

Immunomodulator induces long-term anti-tumor activity

EntreMed, Inc., a clinical-stage biopharmaceutical company developing therapeutic candidates primarily for the treatment of cancer, today reported that three months following administration with ENMD 0996, preclinical animal models showed inhibition of metastases. Data presented demonstrated that ENMD 0996 specifically blocks the activity of basic fibroblast growth factor (FGF-2), a naturally-occurring protein that stimulates angiogenesis, but had no effect on other angiogenesis stimulators.

29 Mar 2004

LAM Pharmaceutical receives approval to sell it's wound gel in China

LAM Pharmaceutical, a biomedical company focused on the development and commercialization of novel wound healing and transdermal drug delivery systems, announced today that the Chinese State Food and Drug Administration ("SFDA") has granted approval for the importation and sale of its patented LAM IPM Wound Gel(TM) in China

24 Mar 2004